Satellite Sessions

A number of programme slots have been set aside by the Scientific Programme Committee for industry sponsored satellite sessions.

All delegates are invited to attend the company satellite symposia. The programmes for these satellite symposia will be designed by the sponsoring companies and vetted by the Scientific Programme Committee to ensure balance, independence, objectivity and scientific rigour.

Saturday 25 April 17:15 - 18:45
Jurriaanse Room
Alexion Satellite Symposium                                                         

Hypophosphatasia: the devastating consequences of low alkaline phosphatase

Chair: Ans van der Ploeg (Rotterdam, The Netherlands)

  • Welcome & introduction
    Ans van der Ploeg (Rotterdam, The Netherlands)
  • Alkaline phosphatase - its crucial role and importance in diagnosis
    Bill Fraser (East Anglia, UK)
  • HPP in infants - respitory, neurological, renal and other consequences
    Raja Padidela (Manchester, UK)
  • HPP in juveniles - skeletal, muscular, rhematologic and other consequences
    Ans van der Ploeg (Rotterdam, The Netherlands)
  • Conclusions and Q & A

Sunday 26 April 12:45 - 14:15
Jurriaanse Room
Amgen Satellite Symposium

Treat to target in osteoporosis - a reality or fantasy?

Chairs: Serge Ferrari (Switzerland) and Claus-C Glueer (Germany)

  • Introduction
  • Claus-C Glueer (Germany)
  • Treat to target - challenges and opportunities
    Eugene McCloskey (UK)
  • Treat to target - a biomechanical perspective
    Philippe Zysset (Switzerland)
  • Treat to target - new evidence
    Serge Ferrari (Switzerland)
  • Panel Discussion
  • All faculty

Monday 27 April 12:45 - 14:15
Grote Room
MSD Satellite Symposium

New and evolving strategies for management of osteoporosis

Chair: Bente Langdahl (Denmark)

  • Welcome and opening remarks
  • Bente Langdahl
  • The role of Cathepsin K in bone homeostasis
    Serge Ferrari
  • Anti-fracture efficacy of Odanacatib in post-menopausal women; Results from teh phase 3 long term Odanacatib fracture trail (LOFT)
    Michael McClung
  • Safety and tolerability of Odanacatib in post-menopausal women; Interim results from teh phase 3 long term Odanacatib fracture trial (LOFT)
    Socrates Papapoulos
  • Panel discussion / Q&A